Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
ID06852950

Continuous Glucose Monitoring for Outpatient Diabetes Management After Hospital Discharge

Led by Vanderbilt University Medical Center · Updated on 2026-03-05

60

Participants Needed

1

Research Sites

N/A

Total Duration

On this page

AI-Summary

What this Trial Is About

This research aims to improve how patients with Type 1 or Type 2 diabetes and hyperglycemia manage their blood sugar after leaving the hospital. It focuses on increasing patient awareness and satisfaction with continuous glucose monitoring systems during the transition from inpatient care to outpatient settings. The study is interventional and compares two different continuous glucose monitoring devices to understand their impact on diabetes care. Participants will be randomly assigned to start using either the Libre 3 Plus or the Dexcom G7 continuous glucose monitor. Both devices connect with smartphone applications to help patients track their glucose levels. The study begins during hospitalization and continues with follow-up telephone visits 2 to 3 weeks after discharge to assess patient experiences and glucose control. During the study, participants will complete questionnaires about their satisfaction with the glucose monitors and the quality of their diabetes care, as well as their familiarity with continuous glucose monitoring. Researchers will also track changes in hemoglobin A1C and glucose management indicators, along with any hospital readmissions related to blood sugar control within 30 days. The total participation involves enrollment during hospitalization and follow-up shortly after discharge.

CONDITIONS

Brief Title

Continuous Glucose Monitoring for Outpatient Diabetes Management After Hospital Discharge

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Non-pregnant adults aged 18 years or older admitted to Vanderbilt University Medical Center
  • Able to provide informed consent
  • Hyperglycemia requiring insulin therapy (subcutaneous injections or insulin pump) during hospital stay and at discharge
  • Blood glucose levels between 70 and 350 mg/dL within 24 hours prior to participation
  • Need for glucose readings at least once daily
  • Adequate mental status and dexterity to use Libre 3 Plus or Dexcom G7 sensors with the respective smartphone apps
Not Eligible

You will not qualify if you...

  • Current or recent (within 3 months) use of Libre 3 Plus or Dexcom G7 continuous glucose monitors
  • Lack of a smartphone compatible with Libre 3 or Dexcom G7 apps
  • Receiving chemotherapy during current hospitalization
  • Planning major surgery within 10 to 15 days
  • Undergoing hemodialysis or peritoneal dialysis
  • Need for vasopressors, intubation, sedation, or ICU admission
  • Use of more than 500 mg/day of vitamin C
  • Use of hydroxyurea
  • Use of acetaminophen exceeding 4 grams per day or 1 gram every 6 hours
  • Significant pitting edema (3+ or greater), such as from cirrhosis with ascites, heart failure, nephrotic syndrome, or poor perfusion
  • Presentation with diabetic ketoacidosis or hyperosmotic nonketotic state
  • Skin allergy to adhesives used in the devices

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Implementation

Duration - Approximately 2 to 3 weeks after discharge

Participants start using either the Libre 3 Plus or Dexcom G7 continuous glucose monitor after hospital discharge to manage their diabetes.

1 enrollment visit and follow-up telephone visit

Trial Site Locations

Total: 1 location

1

Vanderbilt University Medical Center

Nashville, Tennessee, United States, 37232

Actively Recruiting

Loading map...

Research Team

A

Angel Morvant, MD

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

OTHER

Number of Arms

2

Similar Trials

A Phase Ia Clinical Trial to Assess Safety, Tolerability, an...

Hyperglycemia

Actively Recruiting

1 location

A Phase 1b Study of QX1206 in Type 2 Diabetes Mellitus Patie...

Type 2 Diabetes Mellitus (T2DM)

Actively Recruiting

1 location

A Phase 3, Randomized, Open-Label Trial Comparing Efficacy a...

Type 2 Diabetes Mellitus (T2DM)

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here